Page 720 - How to Make Money in Stocks Trilogy
P. 720

24  HOW TO MAKE MONEY IN STOCKS SUCCESS STORIES


           ranked based on superior earnings, strong price performance, and leader-
           ship within their respective industries.

           Stephen Cole
           Stephen is a busy lawyer and an IBD Meetup leader in Sacramento,
           California. His weekend routine includes going through the IBD 50. He
           looks for stocks that are in first or second stage bases, with accelerating
           earnings 25% or greater, and a return on equity of at least 17%. (Return on
           equity measures how efficient a company is with its money.) Stephen builds
           a watch list by looking at the mini chart and the description below each one
           that describes a potential buy point. He sets an alert in his brokerage
           account that lets him know if a stock is nearing that price.
             Stephen bought Transdigm Group in April and had gains of 14% through
           the end of September 2012.


                                    • KEY POINTS •

                • Look for stocks in the IBD 50 that are in first or second
                  stage bases.
                • Stocks should have quarterly earnings of 25% or greater.
                • Return on equity should be at least 17%.

                • The description below the  IBD 50 mini chart will help
                  identify a potential buy point.



           Stuart Auvian
           Stuart is the Meetup leader for the Marin County IBD group located in
           Northern California. He emphasizes to his group the importance of buying
           at least one stock when the market issues a follow-through day. “This puts
           you in the right place psychologically because you’re in the game, rather
           than trying to play catch-up if you get into the market late after a follow-
           through day,” he says. To build his watch list, Stuart pulls four or five stocks
           from the IBD 50 that have top fundamentals. Stuart was successful with
           Alexion Pharmaceuticals, which had earnings growth of 48% and sales
           growth of 44%. Stuart bought the stock in December 2011 and sold on
           March 12 for a 20% gain.
   715   716   717   718   719   720   721   722   723   724   725